相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives
Daniel Lenouvel et al.
ORAL DISEASES (2020)
Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
Emina Torlakovic et al.
MODERN PATHOLOGY (2020)
Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients
C. Kuempers et al.
VIRCHOWS ARCHIV (2020)
Effects of Decalcifying Agents of Variable Duration on PD-L1 Immunohistochemistry
Amanda L. Strickland et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2020)
Biomarkers for immunotherapy response in head and neck cancer
Niki Gavrielatou et al.
CANCER TREATMENT REVIEWS (2020)
Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell-block specimens
Shona Hendry et al.
CYTOPATHOLOGY (2020)
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Sylvie Lantuejoul et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Cytology for PD-L1 testing: A systematic review
John R. Gosney et al.
LUNG CANCER (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-Ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma
Hao Chen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations
Elisa Gremese et al.
CLINICAL IMMUNOLOGY (2020)
Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma
Jeanette E. Eckel-Passow et al.
CANCER MEDICINE (2020)
Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC
Emina Torlakovic et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer
Emily S. Reisenbichler et al.
MODERN PATHOLOGY (2020)
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Lynette Sholl et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Yung-Jue Bang et al.
GASTRIC CANCER (2019)
Analysis of PD-L1 expression in trophoblastic tissues and tumors
Bingjian Lu et al.
HUMAN PATHOLOGY (2019)
Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases
Dennis P. O'Malley et al.
MODERN PATHOLOGY (2019)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
PD-1/PD-L1 Inhibitors in Cervical Cancer
Yuncong Liu et al.
FRONTIERS IN PHARMACOLOGY (2019)
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology Concordance Among 3 Commonly Used and Commercially Available Antibodies
Henning Reis et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study
Anne-Marie Boothman et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer
Angela M. Hong et al.
ORAL ONCOLOGY (2019)
Preanalytics and Precision Pathology Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine
Carolyn C. Compton et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma
Tomoyuki Naito et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen
Maartje van Seijen et al.
VIRCHOWS ARCHIV (2019)
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Anliang Xia et al.
FRONTIERS IN IMMUNOLOGY (2019)
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non small-cell lung cancer: The global, multicenter EXPRESS study
M. Dietel et al.
LUNG CANCER (2019)
Real-World Concordance Across Pathologists for PD-L1 Scoring in Non-Small Cell Lung Cancer: Results from a Large Nationwide Initiative
J. Adam et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer
Erik Thunnissen
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
PD-L1 assessment in urothelial carcinoma: a practical approach
Markus Eckstein et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study
Manish A. Shah et al.
JAMA ONCOLOGY (2019)
New emerging targets in cancer immunotherapy: the role of LAG3
Hannah Christina Puhr et al.
ESMO OPEN (2019)
Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer
Silvia Cantara et al.
ENDOCRINE (2019)
Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study
Francesca Giunchi et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression
Maria Tretiakova et al.
MODERN PATHOLOGY (2018)
PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma
Anjelica Hodgson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
J. Adam et al.
ANNALS OF ONCOLOGY (2018)
Immunohistochemistry of Pulmonary Biomarkers A Perspective From Members of the Pulmonary Pathology Society
Erik Thunnissen et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas
Deepali Jain et al.
CYTOPATHOLOGY (2018)
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
Enrico Munari et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Louis Fehrenbacher et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
Shona Hendry et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms
Christina Koppel et al.
MODERN PATHOLOGY (2018)
Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers.
Kosei Hasegawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis
Jinchul Kim et al.
SCIENTIFIC REPORTS (2018)
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
Andrea Necchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology
Douglas P. Clark
CANCER CYTOPATHOLOGY (2018)
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
Jamaal A. Rehman et al.
MODERN PATHOLOGY (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
De-novo and acquired resistance to immune checkpoint targeting
Nicholas L. Syn et al.
LANCET ONCOLOGY (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
PD-L1 IHC in NSCLC with a global and methodological perspective
Erik Thunnissen et al.
LUNG CANCER (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Accurate PD-L1 Protocols for Non-Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3
Rasmus Roge et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2017)
Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx
Birgit G. Skov et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens
Jonas J. Heymann et al.
CANCER CYTOPATHOLOGY (2017)
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer
Wendy A. Cooper et al.
CLINICAL CANCER RESEARCH (2017)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
P. A. Ott et al.
ANNALS OF ONCOLOGY (2017)
PD-1/PD-L and autoimmunity: A growing relationship
Mohammad Reza Zamani et al.
CELLULAR IMMUNOLOGY (2016)
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C. Rebelatto et al.
DIAGNOSTIC PATHOLOGY (2016)
A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform
Tzahi Neuman et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype
Laveniya Satgunaseelan et al.
PATHOLOGY (2016)
PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
Angela M. Hong et al.
ONCOTARGET (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
Jin Sheng et al.
SCIENTIFIC REPORTS (2016)
Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics
Kelly Elliott et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Antonio Calles et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Standardization of Positive Controls in Diagnostic Immunohistochemistry: Recommendations From the International Ad Hoc Expert Committee
Emina E. Torlakovic et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
A Review of Preanalytical Factors Affecting Molecular, Protein, and Morphological Analysis of Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue How Well Do You Know Your FFPE Specimen?
B. Paige Bass et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Principles of Analytic Validation of Immunohistochemical Assays Guideline From the College of American Pathologists Pathology and Laboratory Quality Center
Patrick L. Fitzgibbons et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
Lei Lu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Data Set for Pathology Reporting of Cutaneous Invasive Melanoma Recommendations From the International Collaboration on Cancer Reporting (ICCR)
Richard A. Scolyer et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Endobronchial ultrasound-guided transbronchial needle aspiration cytology: a state of the art review
S. E. H. Cameron et al.
CYTOPATHOLOGY (2010)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion
Christian Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
A critical role for the programmed death ligand 1 in fetomaternal tolerance
I Guleria et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
